Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS
· Delayed Price · Currency is USD
0.750
-0.150 (-16.67%)
Nov 13, 2024, 9:30 AM EST
Eagle Pharmaceuticals Revenue
Eagle Pharmaceuticals had revenue of $64.65M in the quarter ending June 30, 2023, a decrease of -12.80%. This brings the company's revenue in the last twelve months to $257.55M, down -5.38% year-over-year. In the year 2022, Eagle Pharmaceuticals had annual revenue of $316.61M with 84.56% growth.
Revenue (ttm)
257.55M
Revenue Growth
-5.38%
P/S Ratio
0.04
Revenue / Employee
1.92M
Employees
134
Market Cap
9.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 316.61M | 145.06M | 84.56% |
| Dec 31, 2021 | 171.55M | -16.26M | -8.66% |
| Dec 31, 2020 | 187.80M | -8.09M | -4.13% |
| Dec 31, 2019 | 195.89M | -17.42M | -8.17% |
| Dec 31, 2018 | 213.31M | -23.40M | -9.88% |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Eagle Pharmaceuticals News
- 2 days ago - Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus
- 3 days ago - Eagle Pharmaceuticals names Christopher Krawtschuk as CFO - Seeking Alpha
- 3 days ago - Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - Benzinga
- 9 days ago - Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus
- 23 days ago - INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders - Accesswire
- 5 weeks ago - Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares - GuruFocus
- 2 months ago - Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewsWire
- 7 months ago - Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida - GlobeNewsWire